Wang Feiqian, Numata Kazushi, Nihonmatsu Hiromi, Okada Masahiro, Maeda Shin
Gastroenterological Center, Yokohama City University Medical Center, 4-57 Urafune-cho, Minami-ku, Yokohama, Kanagawa, 232-0024, Japan.
Ultrasound Department, The First Affiliated Hospital of Xi'an Jiaotong University, Shaanxi, 710061, People's Republic of China.
J Med Ultrason (2001). 2020 Apr;47(2):215-237. doi: 10.1007/s10396-019-01001-w. Epub 2020 Jan 16.
Ultrasonography (US) has the overwhelming advantages of not entailing radiation exposure and being a noninvasive, real-time, convenient, easy-to-perform, and relatively inexpensive imaging modality. It is used as the first-line imaging modality for screening, detection, and diagnosis of focal liver lesions (FLLs) [small hepatocellular carcinomas (HCCs), in particular]. However, with the increasing demand for accurate and early diagnosis of small HCCs, newer radiologic methods need to be explored to overcome certain limitations of US. For example, the imaging is easily negatively affected by the presence of gas, rib cage, and subcutaneous fat, and is insensitive for capturing the subtle but vital information on the blood flow. It was in response to this need that new promising technologies such as contrast-enhanced ultrasound and fusion imaging were introduced for the detection of liver lesions. This paper presents an overview of the epidemiology and mechanisms of the development of HCCs, with an emphasis on the application of US in the diagnosis and treatment of FLLs. The aim of this article is to provide the state-of-the-art developments in the imaging diagnosis of FLLs and evaluation of ablation treatment of early HCCs. By keeping abreast of these recent advances, we hope that doctors and researchers working in the field of diagnosis/treatment of liver diseases will be able to discriminate benign FLLs such as regenerative nodules and focal nodular hyperplasia from HCCs, so as to avoid unnecessary repeated tumor biopsies and overtreatment. In particular, we expect that small HCCs or precancerous nodules (such as dysplastic nodules) can be accurately diagnosed and appropriately treated even at an early stage.
超声检查(US)具有诸多显著优势,它无需辐射暴露,是一种无创、实时、便捷、操作简便且相对廉价的成像方式。它被用作筛查、检测和诊断肝脏局灶性病变(FLLs)[尤其是小肝细胞癌(HCCs)]的一线成像方式。然而,随着对小肝癌准确早期诊断需求的增加,需要探索更新的放射学方法来克服超声检查的某些局限性。例如,成像容易受到气体、肋骨和皮下脂肪的负面影响,并且对捕捉血流方面细微但关键的信息不敏感。正是为了满足这一需求,诸如超声造影和融合成像等新的有前景的技术被引入用于肝脏病变的检测。本文概述了肝癌的流行病学和发病机制,重点阐述了超声检查在肝脏局灶性病变诊断和治疗中的应用。本文旨在介绍肝脏局灶性病变成像诊断和早期肝癌消融治疗评估的最新进展。通过紧跟这些最新进展,我们希望从事肝脏疾病诊断/治疗领域的医生和研究人员能够将诸如再生结节和局灶性结节性增生等良性肝脏局灶性病变与肝癌区分开来,从而避免不必要的重复肿瘤活检和过度治疗。特别是,我们期望即使在早期阶段,小肝癌或癌前结节(如发育异常结节)也能够得到准确诊断和适当治疗。